Medical Therapy in IBD: Current Options

To begin the course, please login or register by clicking ENROLL. After logging in, you will be able to complete the pretest and view the video/documents. You will have the option to complete the posttest, evaluation and receive credit. Some courses may have an associated cost.

Step Status
Video/Document(s)
Posttest
Evaluation
Starts On: 7/1/2019: 12:00 AM
Ends On: 6/6/2020: 12:00 AM
Session Type: Internet Activity Enduring Material
Credits: 0.5
Description:

Faculty

Matthew A. Ciorba, MD
Associate Professor, Medicine
Division of Gastroenterology
Director, Inflammatory Bowel Disease Program
Disclosures
Research support / Grants from Procter & Gamble Company, Shire Development Inc., AbbVie Inc., Crohn's & Colitis Foundation of America/CCFA, and Incyte Corp.
Consulting / Employment for Theravance
Speakers Bureau / Honoraria for UCB Pharmaceuticals, Abbott and Takeda Pharmaceuticals, Inc.

Presenters should indicate if speaking off label. This activity originated as a presentation at the CME activity, Multidisciplinary Management of Inflammatory Bowel Diseases: New Advances and Case Studies, April 21, 2018, which was supported in part by Celgene Corporation, Gilead Sciences, Inc., Janssen Biotech, Inc., Takeda Pharmaceuticals, Prometheus Laboratories Inc., and Salix Pharmaceuticals, Inc., a Division of Valeant Pharmaceuticals .

Planning Committee

Mark Bruns, RN, MHA, GCRN, Clinical Nurse Coordinator, Division of Gastroenterology
Financial Relationships: Speaker has nothing to disclose.

Joanna Joyce Davidson Gilbertsen, RN, BSN, Clinical Nurse Coordinator, Division of Gastroenterology
Financial Relationships: • Speaker's Bureau/Honoraria: AbbVie, Inc

Eli N, Deal, PharmD, FCCP, BCPS, Clinical Pharmacy Specialist, Internal Medicine, Barnes-Jewish Hospital
Financial Relationships: Speaker has nothing to disclose.

Jill Elwing, MD, Assistant Professor of Medicine, Division of Gastroenterology (Independent Reviewer)
Financial Relationships: Speaker has nothing to disclose

Andrew La Brier, Inflammatory Bowel Diseases Program Manager, Division of Gastroenterology
Financial Relationships: Speaker has nothing to disclose.

Dan Schneiderjohn, MPH, Regional Education and Support Manager Crohn's and Colitis Foundation Mid-America Chapter
Financial Relationships: Speaker has nothing to disclose.

Objectives: The intended result of this activity is increased knowledge/competence, and upon completion of this course, participants should be able to:
  • Review use of conventional and biologic therapies in the treatment of Crohn's Disease and Ulcerative Colitis
  • Review principles of managing by "Step-Up" and "Treat-to-Target"
Additional Information:
Target Audience: This course is designed for gastroenterologists, colon and rectal surgeons, GI surgeons, general surgeons, internists, family physicians, abdominal radiologists, dermatologists, emergency medicine physician assistants, pharmacists, nurses, nurse practitioners and other clinicians interested in, or involved with the diagnosis and treatment of patients with inflammatory bowel diseases.

Date
Publication Date: July 1, 2019
Expiration Date: June 6, 2020
Accreditation Information:
wustlcme
In support of improving patient care, this activity has been planned and implemented by Washington University School of Medicine in St. Louis, the Crohn's and Colitis Foundation Mid- America Chapter. Washington University School of Medicine in St. Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Awarded for this Activity:
Credit Statement: American Medical Association (AMA Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of .5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
References:
  • Lichtenstein GR, et al. Am J Gastroenterol 2012;107(9):1409-1422.
  • Rutgeerts P, et al. N Engl J Med 2005;353:2462-2476
  • Sandborn WJ, et al. Gastroenterology 2012;142:257-265
  • Feagan B, et al NEJM 2016; 375:1946-1960.
  • Sands BE, et al. Gastroenterology 2014;147:618-627
Disclosure Information: It is the policy of Washington University School of Medicine in St. Louis, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational activities. All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations. Any potential conflicts were addressed and resolved.

Presenters are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.

Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis. These presentations are not an endorsement of any commercial interests.

These presentations are the views and experiences of the presenters. The presenters' views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the provider for CME credits.
Categories: Gastroenterology, General Medicine


Powered By AI 4.5